**Review Article**

**The Proportion of Regulatory T Cells in Patients with Ankylosing Spondylitis: A Meta-Analysis**

Na-Lin Lai,1 Sheng-Xiao Zhang,1 Jia Wang,1 Jia-Qian Zhang,1 Cai-Hong Wang,1 Chong Gao,2 and Xiao-Feng Li1

1Department of Rheumatology, The Second Hospital of Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi 030001, China
2Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Xiao-Feng Li; lxf_9859@sxmu.edu.cn

Received 24 March 2019; Revised 19 July 2019; Accepted 30 August 2019; Published 23 October 2019

Academic Editor: Nejat K. Egilmez

Copyright © 2019 Na-Lin Lai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objective.** Accumulating evidence indicates that regulatory T cells (Tregs) may be involved in the pathogenesis of ankylosing spondylitis (AS). As different markers have been used to identify Tregs, some studies on the proportions of Tregs in AS patients have generated considerable controversy. To clarify the status of Tregs in such patients, we determine the proportion changes of peripheral Tregs during development of the disease, with different cellular markers. **Methods.** We systematically searched Embase, PubMed, Cochrane, Web of Knowledge, FDA.gov, and Clinical Trials.gov for the studies reporting the proportion of Tregs in AS patients. Using the PRISMA guidelines, we performed a random-effects meta-analysis of the frequencies of peripheral Tregs defined in different ways. Inconsistency was evaluated using the I-squared index ($I^2$), and publication bias was assessed by examining funnel plot asymmetry using the Beggar and Egger tests. **Results.** A total 29 studies involving 1732 participants were included in the meta-analysis. Their conclusions of using the diversity of Tregs surface markers were inconsistent with each other. No significant difference in the proportions of Tregs was evident regardless of the definitions used ($[-0.709, (-1.455, 0.037), p = 0.063], I^2 = 97.3\%$). Six studies used “single CD25-positive” cells as Tregs, which revealed a significant increase in AS patients compared with healthy blood donors [0.736, (0.138, 1.334), $p = 0.016, I^2 = 80.7\%$]. Notably, the proportions of “CD4+CD25+FOXP3−”, “CD4+CD25highCD127low/−”, or “CD4+CD25−CD127low” T cells were lower in AS patients [−2.856, (−4.645, −1.066), $p = 0.002$; −1.812, (−2.648, −0.977), $p < 0.001$; −1.12, (−1.605, −0.635), $p < 0.001$]. Tregs defined as “CD25high,” “CD25bright”, “CD25bright/highCD127low/−”, “CD4+FOXP3−”, “CD4+CD25highFOXP3−”, or “CD4+CD25−CD127−” did not differ in proportion between AS patients and healthy blood donors. **Conclusions.** The levels of Tregs varied based on the cellular identification markers used. The proportions of CD4+CD25FOXP3−Tregs, CD4+CD25highCD127low/−, or CD4+CD25−CD127low in blood of AS patients were significantly decreased as compared with those in healthy blood donors, and our findings lend support to the idea that the Treg status of AS patients is important. And we recommend the above as the best definition of Tregs when evaluating the status of such patients.

1. Introduction

Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, asymmetrical peripheral oligoarthritis, enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease, which can lead to structural and functional impairments and a decrease in quality of life [1]. To date, the disease etiology remains unclear. Reduced proportion and deficient function of CD4+ regulatory T cells (Tregs, with immune modulation and suppression) have been implicated in the pathogenesis of different immune-mediated rheumatic diseases [2–4]. In the case of AS, few studies have been carried out to analyze the levels of Tregs in the peripheral blood of patients; however, low percentages [5–8] or functional impairment of Tregs [9, 10] has been reported in the peripheral blood (PB) of patients with AS, suggesting an imbalance between Tregs and the adaptive immune response. Moreover, AS patients treated with anti-TNF therapy showed...
similar levels of Treg cells to those observed in healthy subjects [11]. These data suggest a possible role of Tregs in AS.

However, initial studies of Treg status in PB of patients with AS are controversial. One reason for the inconsistencies may be the multiple phenotypes of Tregs, which have been identified using different markers [12]. Tregs were first described as a peripheral CD4+ subset expressing interleukin-2 (IL-2) receptor alpha chains (CD25) [13]. As early as 2004, Cao et al. [14] used CD4+CD25bright to identify peripheral Tregs in peripheral blood of AS patients. However, CD25 was expressed not only on Tregs but also on activated cells lacking regulatory functions, although the CD4+ T cell subset expressed the highest levels of CD25 (CD4+, CD25high) and exhibited in vitro immunosuppressive features [15]. Forkhead box protein P3 (FOXP3), a transcription factor expressed at high levels in authentic Tregs, plays a key role in Treg development and is thought to be one of the most specific Treg cell markers [16]. Since 2008, scholars have been studying the proportion and function of peripheral FOXP3+Tregs of AS patients [9, 17]. However, the marker cannot be used to sort live cells, as the protein is intracellular. In addition, CD127, the alpha chain of the IL-7 receptor, was reported to be upregulated on human T cells after activation and downregulated on Tregs [18]. Thus, co-staining for CD127 and CD25 has been proposed to efficiently discriminate between Tregs and activated T cells [19]. The study of CD4+CD25−CD127− Tregs in AS patients began in 2011. Zhao et al. used CD25+CD127− to define peripheral Tregs in new-onset AS patients firstly [6]. Furthermore, CD8− CD127+ T cell is a newly discovered natural immune regulatory T cells with immune negative regulation function [20], which may be involved in the pathogenesis and disease progression of AS [21]. The available data on the proportions and phenotypes of Tregs of AS patients are contradictory; some studies using the same or different markers to analyze peripheral Tregs of AS patients have obtained different or even opposite results [22–25].

To better understand Treg dysfunctions in patients with AS, we meta-analyzed reports documenting the proportion of peripheral Treg cells among CD4+ T cells in the PB of patients with AS, as well as healthy blood donors in this study.

2. Methods

2.1. Data Sources and Searches. This meta-analysis was consistent with that of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement, and it had been registered at the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42019120790). We searched for relevant studies published between January 1, 1950, and November 1, 2018, using PubMed, Embase, Cochrane, Web of Knowledge, Clinical Trials.gov, and FDA.gov, with no restrictions in terms of the primary outcome or publication language. We used the MeSH terms “Spondylitis, Ankylosing” and “T-lymphocytes, regulatory” and their combination. All potentially eligible studies were considered except for reviews and murine experiments. Key articles listed in the references were retrieved manually.

2.2. Study Selection and Data Extraction. The inclusion criteria were evaluation of the proportion of Tregs among CD4+ T cells of AS patients using the 1984 Modified New York AS Criteria [26], available as a full text article, and information on the number of patients and healthy blood donors. Two investigators independently selected and identified relevant publications, and a third investigator resolved any disagreements. The evidence levels of the studies were assessed based on the 2011 guidelines of the Oxford Centre for Evidence-Based Medicine. Quality assessment was done with the Newcastle-Ottawa Quality Assessment Scale, which can be used to assess the quality of nonrandomized studies.

We recorded patient baseline characteristics and their country of origin, the year of publication, the number of patients and healthy blood donors, the definition of Tregs used (including CD4+CD25+, CD4+CD25 bright, CD4+CD25−, CD25−FOXP3+, FOXP3+, CD25−FOXP3+, CD25+FOXP3+, CD25+CD127+, CD25+CD127−, CD25+CD127−FOX3+, and CD25−CD127−FOX3+), and the mean (or median) and standard deviation (SD) of the proportion of Tregs of AS patients. Data on the proportion of Tregs in patients with HLA-B27(+) and HLA-B27(−) were also extracted.

2.3. Statistical Analysis. For continuous outcomes (the proportions of Tregs among CD4+/CD8+ T cells of patients with AS and healthy blood donors), we calculated standardized mean differences (SMDs) and compared these values using a random-effects model (REM) (the DerSimonian and Laird method) [27]. When Treg percentages were reported as medians with interquartile ranges (IQRs), we calculated means and SD (SD = IQR/1.35). The Cochrane chi-squared test was used to explore between-study heterogeneity. As heterogeneity was high (I² > 75%), we drew forest plots and performed subgroup analyses to explore the possible effects of study characteristics on outcomes. Publication bias was assessed by examining funnel plot asymmetry using the Begg and Egger tests (p ≥ 0.05). A preplanned sensitivity analysis was performed by omitting each study individually and calculating the remaining pooled effect. All statistical analyses were conducted using Stata software (ver. 12.0).

3. Results

3.1. Study Characteristics. We identified 564 studies. And 29 of them (with data on 980 patients and 752 healthy blood donors) were included in the analysis (Figure 1), and all of them used a reliable flow cytometric analysis to detect the proportions of peripheral Tregs. The details are shown in Table 1. The average age of the AS patients was between 24.8 and 52.13 years, the proportion of males ranged from 0 to 100%, the average disease duration was from 1.6 to 13.3 years, the average erythrocyte sedimentation rate (ESR) was from 15.2 to 57.3 mm/hour, the average C-reactive protein (CRP) was from 6.63 to 77.1 mg/l, and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [28] from was 1.19 to 51.94. Patients were treated with glucocorticoids, NSAIDs, DMARDs, immunosuppressants including cyclophosphamide (CTX) and cyclosporine, and biological agents.
All healthy blood donors were age and sex matched, healthy, and without any autoimmune disease. All studies were poor-quality case-control studies or case series; thus, they were all of evidence level 4. We regarded all studies as case-control studies and scored them using the Newcastle-Ottawa Quality Assessment Scale (NOQAS); all studies had a score of 3–5.

3.2. The Proportion of Peripheral Tregs of AS Patients. First, we performed a meta-analysis of the proportion of Tregs between AS patients and healthy blood donors when Tregs were defined as “CD4+CD25+” cells. A pooled analysis of all 6 trials [14, 22, 23, 29–31] revealed a significant increase in the proportion of Tregs in AS patients compared with healthy blood donors [0.736, (0.138, 1.334), p = 0.016] with statistically significant between-study heterogeneity (I^2 = 80.7%, p < 0.001) and no significant between-study publication bias detected by the Egger test (t = 0.72, p = 0.513). In detail, we found a significant increase in the proportion of Tregs between AS patients and healthy blood donors when Tregs were defined as “CD4+CD25^bright” cells [0.846, (0.401, 1.291), p < 0.001] [31]. However, the proportion of Tregs defined as “CD4+CD25^{highn}” cells [0.892, (−0.078, 1.862), p = 0.071] [22, 23, 29, 30] and as “CD4+CD25^{brightn}” cells [0.123, (−0.596, 0.842), p = 0.737] [14] did not differ significantly between patients and healthy blood donors (Table 2).

Then, we analyzed studies in which Tregs were defined as “FOXP3^+” cells. A pooled analysis of all 18 trials [5, 7, 8, 11, 17, 25, 31–38] revealed a significant decrease in the proportion of such Tregs between AS patients and healthy blood donors [-1.094, (−1.966, −0.042), p = 0.041]. Statistically significant heterogeneity was evident among the studies (I^2 = 97.9%, p < 0.001). The Egger test detected no publication bias (t = 0.97, p = 0.795). Among the studies, 9 [5, 7, 8, 25,
Table 1: Characteristics of the individual studies included in the meta-analysis.

| Author (ref.)         | Publish year | Country | EL | Q | Case numbers | Tregs' definition | % of Tregs among CD4+ T cells [mean (or median) ± SD] | p   |
|-----------------------|--------------|---------|----|---|--------------|-------------------|--------------------------------------------------|-----|
| Duojia Cao et al. [14]| 2004         | Sweden  | 4  | 6 | 10           | 29                | CD4+CD25highCD4+ | 1.31 ± 0.68, 1.23 ± 0.64 ns |
| Jau-Ling Suen et al. [17]| 2008       | Taiwan, China | 4 | 6 | 23           | 36                | CD4+CD25highFOXP3+ | 0.97 ± 0.33, 0.86 ± 0.39 ns |
| Éric Toussirot et al. [32]| 2009       | France  | 4 | 6 | 32           | 15                | CD4+CD25FOXP3+   | 8.2 ± 0.61, 7.94 ± 1.04 ns |
| Frauke Forger et al. [29]| 2009        | Swiss   | 4 | 7 | 15           | 18                | CD4+CD25high     | 2.22 ± 1.47, 2.12 ± 1.42 <0.01 |
| Francesco Ciccia et al. [22]| 2010       | Italy   | 4 | 8 | 18           | 15                | CD4+CD25high     | 1.08 ± 0.4, 0.25 ± 0.12 <0.05 |
| Christian Dejaco et al. [23]| 2010       | Austria | 4 | 5 | 22           | 17                | CD4+CD25high     | 13.54 ± 16.55, 3.08 ± 2.48 ns |
| Heiner Appel et al. [33]| 2011        | Germany | 4 | 6 | 19           | 20                | CD4+FOXP3+       | 5.55 ± 2.54, 5.18 ± 1.99 ns |
| Ming-Han Chen et al. [30]| 2011        | Taiwan, China | 4 | 7 | 23           | 25                | CD4+CD25high     | 2.18 ± 0.11, 2.16 ± 0.1 ns |
| Yanfeng Wu et al. [5]  | 2011         | China   | 4 | 8 | 51           | 49                | CD4+CD25FOXP3+   | 1.23 ± 0.13, 2.56 ± 0.16 <0.001 |
| S-S Zhao et al. [6]  | 2011         | China   | 4 | 8 | 14           | 18                | CD4+CD25highCD127low | 0.57 ± 0.29, 1.65 ± 0.75 <0.001 |
| Katayoon Bidal et al. [46]| 2012        | Iran    | 4 | 7 | 18           | 17                | CD4+FOXP3+       | 9.7 ± 1.2, 16.1 ± 3 0.048 |
| Leonardo Limon-Camacho et al. [11]| 2012 | Mexico | 4 | 5 | 39           | 25                | CD4+FOXP3+       | 7.3 ± 1.3, 5.3 ± 1.7 0.01 |
| Yong Gao et al. [34]  | 2012         | China   | 4 | 8 | 40           | 37                | CD4+CD25FOXP3+   | 3.77 ± 0.81, 4.69 ± 1.23 <0.05 |
| Li Xueyi et al. [7]  | 2013         | China   | 4 | 6 | 222          | 68                | CD4+CD25FOXP3+   | 2.14 ± 0.44, 4.99 ± 0.49 <0.001 |
| Lingying Ye et al. [62]| 2013         | China   | 4 | 6 | 21           | 22                | CD4+CD45RO+FOXP3+high | 0.48 ± 0.07, 0.73 ± 0.07 <0.05 |
| Wei Ji et al. [39]   | 2014         | China   | 4 | 7 | 20           | 20                | CD4+CD25CD127low | 40.1 ± 17.5, 58.6 ± 10.2 <0.05 |
| Zhang Xin et al. [8]  | 2014         | China   | 4 | 5 | 10           | 10                | CD4+CD25FOXP3+   | 2.72 ± 0.26, 5.17 ± 0.31 <0.001 |
| Hsien-Tzung Liao et al. [31]| 2015       | Taiwan, China | 4 | 8 | 69           | 30                | CD4+CD25FOXP3+   | 1.73 ± 1.08, 1.51 ± 0.48 <0.001 |
| Yuxing Shan et al. [24]| 2015         | China   | 4 | 6 | 20           | 10                | CD4+FOXP3+CXCR5+ | 5.57 ± 1.28, 3.08 ± 0.59 <0.0001 |
| Chenggong Wang et al. [35]| 2015        | China   | 4 | 6 | 45           | 20                | CD4+CD25FOXP3+   | 1.81 ± 0.81, 1.23 ± 0.52 ns |
| Elliott TJ Dunn et al. [36]| 2016        | New Zealand | 4 | 7 | 6            | 10                | CD4+FOXP3+CD127high | 1.43 ± 0.37, 0.43 ± 0.15 ns |
| Huifang Guo et al. [9] | 2016         | China   | 4 | 8 | 39           | 17                | CD4+CD25FOXP3+   | 5.62 ± 0.4, 5.89 ± 0.2 ns |
| Zhongliang Duan et al. [40]| 2017        | China   | 4 | 7 | 21           | 16                | CD4+CD25CD127low | 2.7 ± 0.8, 3.47 ± 0.83 0.03 |
| Zofia Gula et al. [37]| 2017         | Poland  | 4 | 7 | 48           | 23                | CD4+FOXP3+       | 28.83 ± 11.71, 34.39 ± 20.65 ns |
| Dan Xu et al. [25]   | 2017         | China   | 4 | 7 | 17           | 93                | CD4+CD25FOXP3+   | 22.58 ± 12.8, 35.57 ± 6.48 <0.01 |
| Mingfei Wang et al. [10]| 2018        | China   | 4 | 7 | 26           | 26                | CD4+CD25FOXP3+CD127+ | 6.32 ± 1.5, 5.44 ± 1.02 <0.05 |
| Mohammad Javad Fattah et al. [38]. | 2018 | Iran     | 4 | 7 | 30           | 15                | CD4+CD25FOXP3+   | 2.7 ± 0.23, 3.3 ± 0.47 0.45 |
| Renfang Han et al. [21]| 2018         | China   | 4 | 6 | 40           | 40                | CD8+CD122+       | 10.72 ± 6.32, 1.21 ± 0.82 <0.05 |
| Sonja Dulic et al. [41]| 2018         | Hungary | 4 | 8 | 22           | 10                | CD4+CD25CD127−   | 5.708 ± 2.05, 5.715 ± 0.79 ns |

AS: ankylosing spondylitis; HD: healthy donors. *Evidence level (EL) of each study was based on Oxford Centre for Evidence-Based Medicine 2011. Quality (Q) of each study was based on the Newcastle-Ottawa Quality.

31, 32, 34, 35, 38] used “CD4+CD25highFOXP3+” to define Tregs, which showed that the proportion of Tregs in AS patients appeared to be lower than in healthy blood donors [−2.856, (−4.645, −1.066), p = 0.002]. However, pooling of these data with those of other studies [17, 31] identifying Tregs as “CD4+CD25low/FoxP3+” cells revealed a higher proportion of Tregs in patients than in healthy blood donors [0.683, (0.161, 1.206), p = 0.01]. Tregs were identified as simply “FOXP3+” cells [11, 33, 37]; and “CD25highFOXP3+” cells [9, 17, 36] [0.383, (−0.663, 1.429), p = 0.473; 0.868, (−0.756, 2.492), p = 0.295] were not shown to be significantly different between patients and healthy blood donors (Table 2). Finally, the other four groups [6, 39–41] that used “CD127−negative” in CD4+ T cell subgroups to define Tregs showed that such cell numbers decreased in AS patients [−1.003, (−1.713, −0.294), p = 0.006] with statistical
heterogeneity ($I^2 = 73.1\%$, $p = 0.011$) and no publication bias ($t = -0.37$, $p = 0.747$). More specifically, pooling the data of studies in which Tregs were identified as “CD4+CD25highCD127low” cells [6] and “CD4+CD25+CD127low” cells [39, 40] revealed a significant decrease between AS patients and healthy blood donors [-1.812, (-2.648, -0.977), $p < 0.001$; -1.12, (-1.605, -0.635), $p < 0.001$], but no significant difference was observed when Tregs were defined as “CD4+CD25+CD127+” cells [-0.004, (-0.751, 0.744), $p = 0.992$] [41] (Table 2).

Due to the heterogeneity in the meta-analysis, the random-effects model was applied in preparing forest plots. We hypothesized that the significant heterogeneity might have been caused by differences in the experimental methods, and clinical type and severity of disease among the different studies.

3.3 Disease Activity and the Proportion of Tregs in PB. To further assess the effect of disease activity, we analyzed 2 studies [9, 21] that reported the proportion of Tregs in active and stable AS patients regardless of the Tregs definitions used (Figure 3). All of these 2 studies used the Ankylosing Spondylitis Disease Activity Score (ASDAS) [42-44] to evaluate the disease activity. Guo H. et al. [9] found no significant differences in the percentages of Tregs among patients with active AS and patients with stable AS, but Han R. et al. [21] showed a significant increase. We found no difference in the proportion of Tregs in patients with active compared with stable AS [-0.234, (-3.267, 2.799), $p = 0.880$]. The heterogeneity, as assessed by the $I^2$ statistic, was 95.3% ($p < 0.0001$).

4. Discussion

It is now widely accepted that Treg cells play a key role in the maintenance of immune tolerance and homeostasis [3, 45]. However, the role of Tregs in peripheral immune tolerance in patients with AS has not been fully elucidated in previous studies [7, 21, 31]. During the process, the markers used in
the identification of Tregs are inconsistent by flow cytometry in previous studies; therefore, the proportion of peripheral Treg of AS patients has always been reported controversially [5, 24, 29, 46]. Our overall meta-analysis found no significant difference in Treg proportions between patients and healthy blood donors, although significant between-study heterogeneity was evident. We considered that the primary reasons for such unexpected results were due to inconsistent definitions of Tregs based on diverse markers used; thus, we subanalyzed the Treg data by the markers used for Treg identification, including CD25, FOXP3, and CD127.

Currently, researches on Tregs mainly focus on CD4+ Tregs. Expression of CD25 (α chain of family IL-2R) correlates positively with Treg functionality [47]. The Treg-suppressive capacity is restricted to the CD4+ T cells that express the highest levels of CD25 [48]. We found out that AS patients had a higher proportion of Tregs termed “single CD25-positive” than had healthy blood donors. However, when Tregs were defined as “CD4+CD25high” or “CD4+CD25bright,” no significant differences were found between AS patients and healthy blood donors. And other activated CD4+ T cells also express CD25 [45, 48], indicating that use of the surface marker CD25 alone is inadequate. In 2008, Han G. et al. [49] found out that CD25high cells that included a large proportion of FOXP3− cells could not be classified as Tregs. The expressions of the transcription factor FOXP3 or other markers are considered more specific for the identification of Tregs than CD25 [50].

### Table 2: Subgroup analysis based on different definitions of Tregs in PB of patients with AS.

| Definition of Tregs | Number of studies | Test of association | Test of heterogeneity | Egger’s test |
|--------------------|-------------------|---------------------|-----------------------|--------------|
|                    |                   | SMD (95% CI)        | p value               | $I^2$ (p value) |
| Single CD25-positive | 6                 | 0.736 (0.138, 1.334) | 0.016                 | 80.7% (0.001) | 0.72 (0.513) |
| CD4+CD25+           | 1                 | 0.846 (0.401, 1.291) | <0.001               | –             | –             |
| CD4+CD25high        | 4                 | 0.892 (−0.078, 1.862) | 0.071                 | 87% (0.001)  | 2.74 (0.112) |
| CD4+CD25bright      | 1                 | 0.123 (−0.596, 0.842) | 0.737                 | –             | –             |
| Associated with FOXP3-positive | 18 | −1.004 (−1.966, −0.042) | 0.041                | 97.9% (0.001) | 0.97 (0.795) |
| CD4+FOXP3+          | 3                 | 0.383 (−0.663, 1.429) | 0.473                 | 90.4% (0.001) | −11.62 (0.143) |
| CD4+CD25FOXP3+      | 9                 | −2.856 (−4.645, −1.066) | 0.002                | 98.6% (0.001) | 6.06 (0.42)  |
| CD4+CD25highFOXP3+  | 3                 | 0.868 (−0.756, 2.492) | 0.295                 | 92.6% (0.001) | 2.91 (0.862) |
| CD4+CD25low/FOPX3+  | 3                 | 0.683 (0.161, 1.206) | 0.01                  | 68.4% (0.042) | 9.58 (0.783) |
| Associated with CD127-negative | 4 | −1.003 (−1.713, −0.294) | 0.006                | 73.1% (0.011) | −0.37 (0.747) |
| CD4+CD25highCD127low− | 1 | −1.812 (−2.648, −0.977) | <0.001             | –             | –             |
| CD4+CD25CD127flow   | 2                 | −1.12 (−1.605, −0.635) | <0.001               | 0.0% (0.486)  | –             |
| CD4+CD25−CD127      | 1                 | −0.004 (−0.751, 0.744) | 0.992                | –             | –             |
| PB: peripheral blood; AS: ankylosing spondylitis; SMD: standard mean difference; CI: confidence interval; $I^2$: I-squared index. Magnitude of Cohen’s d effect size (SMD): 0.2–0.5, small effect; 0.5–0.8, medium effect; and ≥0.8, large effect.

### Figure 3: Forest plot of the overall meta-analysis of regulatory T cell (Treg) proportions in peripheral blood (PB), regardless of the Treg definition used, in patients with active and stable AS.
FOXP3 is a pivotal regulator of Treg fictional gene expression, being required for both Treg generation and survival [51]. The mutations of the FOXP3 gene disturb the function of Tregs, therefore resulting in the development of various autoimmune diseases [52]. Decreased FOXP3 expression causes an immune disease by subverting the suppressive function of Treg cells and converting Treg cells into effector cells [53]. However, when Treg were defined as “FOXP3-positive” cells, the proportions of such cells did not differ between AS patients and healthy blood donors because the definitions of Tregs were complicated by the addition of CD25 status, giving “CD25-negative and FOXP3-positive” and “CD25 and FOXP3 double positive.” We also found that AS patients had a higher proportion of Treg% "CD4+CD25low/−FOXP3+" than had healthy blood donors. This phenomenon may be explained by the findings that the CD4+CD25low/FOPX3+ cells were dysfunctional Tregs [54, 55] and may even be previously activated conventional T cells [56].

However, the detection of FOXP3 requires cell permeabilization, thereby preventing isolation of viable Tregs. Subsequently, the extracellular marker CD127 was established for the identification of Tregs [57–59]. Some scholars believe that CD4+CD25−CD127low− is the best surface marker of natural Tregs and alive Tregs, which not only can avoid interference of other activated T cells, but can also be used to conduct preliminary functional studies [19]. We found that the ratio of "CD127-negative" in peripheral blood of patients with AS was significantly lower than that of the control group, further suggesting that CD127 combined with other markers could indeed be used to label Tregs.

CD8+Tregs are similar to CD4+Treg and also have immunomodulatory effects. However, due to the lack of specific surface markers, few studies have been conducted on CD8+Treg [60, 61]. In 2015, Churland G. et al. [61] have found that the proportion of CD8+Tregs in the peripheral blood of healthy people is less than one-tenth of that of CD4+Tregs, which makes the study of CD8+Tregs more difficult. In this study, we found that only one study [21] reported the expression of CD8+Treg in peripheral blood of patients with AS, and a comprehensive analysis showed that there was a higher proportion of CD8+Treg in AS group than in the healthy control group. The specific marker, expression, and function of CD8+Treg need further study.

Some studies have used other markers to indicate different subsets of Tregs [24, 46, 62]. Human FOXP3+ cells have been subdivided into three functionally and phenotypically distinct subsets [63]: naive Tregs (FOXp3+CD45RA+), short-lived and highly suppressive activated Tregs (FOXp3highCD45RA+), and non-Tregs (FOXp3lowCD45RA–). Although human naturally occurring Tregs may express either CD45RA or CD45RO, the majority of natural Tregs in adults are CD45RO+, which increases significantly with age [64, 65]. Ye L. et al. [62] found that in AS patients, the frequencies of effector Tregs (CD4+FOXp3highCD45RO+) and naive Tregs (CD4+FOXp3lowCD45RO–) were decreased. Tbet is an immune cell-specific member of the T-box family of transcription factors, which is required for the functional fitness of pTregs (also known as induced or adaptive Tregs [66–68]). Only Bidad K. [46] observed that FOXP3+CD4+ROyt Tbet+ Tregs in AS patients were significantly lower than in healthy blood donors. A specialized subset of Tregs that are characterized by a high expression level of CXC chemokine receptor 5 (CXCR5), T follicular regulatory (Tfr) cells are important for the control of humoral immune responses [69, 70]. To date, it is still challenging to value the real status of above Treg subsets in patients with AS.

Further, the controversial status of Tregs in PB of AS patients might also be related to the different disease status, such as different treatment, disease activity, or markers of inflammation. It appears that the effects of corticosteroids (CS) on Treg numbers in patients with autoimmune diseases are disease-specific [71]. Treg cell numbers increased in CS-treated patients with SLE [72, 73] but decreased in CS-treated patients with psoriasis [74] and was not clearly defined in multiple sclerosis patients [75, 76]. Some studies found that disease-modifying antirheumatic drugs (DMARDs) can normalize the distribution of Tregs in RA patients [77–79]. Long-term anti-TNF therapy may increase Tregs in AS and other autoimmune diseases [41, 62, 80]. However, studies about CS and DMARDs on peripheral blood Tregs in AS patients are still lacking. In addition to drugs, disease activity also affects the proportion of peripheral blood Tregs [81, 82]. But our subgroup analysis found no difference in the proportion of Tregs in patients with active compared with stable AS. However, this conclusion needs to be confirmed by more studies on the proportion of Tregs and the activity of AS. One study also observed that the highest correlation coefficient was between CD4+CD25+FoxP3+Tregs and CRP or ESR [31]. But the true relationship between Tregs and inflammatory markers needs further studies.

Our meta-analysis had several limitations. Firstly, severity of the disease and clinical subtypes in AS patients were not consistent across studies. Moreover, although we did a subgroup analysis of disease activity, the results are questionable due to the small number of studies included. Second, we did not consider disease duration or treatment, as both the drugs used and disease staging were inconsistent; however, these factors might affect the proportion of Tregs in PB. Thirdly, there were differences in experimental methods between studies. A flow cytometric expert must run through all experiments: Some of the flow cytometric assays in the papers used here might even be disqualified. Meanwhile, the definition of Tregs in some studies also included CD127low or CD25high rather than completely the same definition makers. Moreover, Tregs are usually evaluated in PB, in which tissue Treg status may fluctuate.

5. Conclusion

Our study suggests that the reported variations of Treg status among AS patients are due to using inconsistent definitions or markers for Tregs. We found the best definition of Tregs as CD4+CD25+FOXP3+ or CD4+CD25high/CD127low−. Further studies are needed to validate our results in independent cohorts of patients with larger sample sizes using the above definitions of Tregs as accurate and standard definition of
Tregs. Our findings lend support to the idea that the Treg status of AS patients is important.

**Disclosure**

National Science Foundation of China had no involvement in the study design; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

NLL, SXZ, and XFL participated in the study design. NLL, JW, and IQZ participated in the data collection and interpreted the data. NLL and SXZ performed the statistical analysis under the supervision of CHW and XFL. NLL and SXZ wrote the draft manuscript, and CHW and CG helped revise the manuscript. All authors read and approved the final manuscript. Na–Lin Lai and Sheng–Xiao Zhang contributed to the work equally and should be regarded as co-first authors.

**Acknowledgments**

We wish to acknowledge funding in support of XFL and CHW by the National Science Foundation of China (81871295 and 81471618).

**Supplementary Materials**

Supplementary Table 1: background of AS patients in each study. Supplementary Figure 1: forest plot of the overall meta-analysis of regulatory T cell (Treg) proportions in peripheral blood (PB), identified with single CD25-positive, between ankylosing spondylitis (AS) patients and healthy blood donors (HD). Supplementary Figure 2: forest plot of the overall meta-analysis of regulatory T cell (Treg) proportions in peripheral blood (PB), identified with FOXP3-positive, between ankylosing spondylitis (AS) patients and healthy blood donors (HD). Supplementary Figure 3: forest plot of the overall meta-analysis of regulatory T cell (Treg) proportions in peripheral blood (PB), identified with CD127-negative, between ankylosing spondylitis (AS) patients and healthy blood donors (HD). (Supplementary Materials)

**References**

[1] J. Braun and J. Sieper, “Ankylosing spondylitis,” *The Lancet*, vol. 369, no. 9570, pp. 1379–1390, 2007.

[2] C. Dejaco, C. Duftner, B. Grubeck-Loebenstein, and M. Schirmer, “Imbalance of regulatory T cells in human autoimmune diseases,” *Immunology*, vol. 117, no. 3, pp. 289–300, 2006.

[3] A. Liston and D. H. Gray, “Homeostatic control of regulatory T cell diversity,” *Nature Reviews Immunology*, vol. 14, no. 3, pp. 154–165, 2014.

[4] A. M. Gizinski and D. A. Fox, “T cell subsets and their role in the pathogenesis of rheumatic disease,” *Current Opinion in Rheumatology*, vol. 26, no. 2, pp. 204–210, 2014.

[5] Y. Wu, M. Ren, R. Yang et al., “Reduced immunomodulation potential of bone marrow–derived mesenchymal stem cells induced CCR4,” *Arthritis & Th17/Treg cell subset imbalance in ankylosing spondylitis,* *Arthritis & Therapy*, vol. 13, no. 1, article R29, 2011.

[6] S. S. Zhao, J. W. Hu, J. Wang, X.-J. Lou, and L.-L. Zhou, “Inverse correlation between CD4+CD25hiCD127low regulatory T-cells and serum immunoglobulin A in patients with new-onset ankylosing spondylitis,” *The Journal of International Medical Research*, vol. 39, no. 5, pp. 1968–1974, 2011.

[7] L. Xueyi, C. Lina, W. Zhenbiao, H. Qing, L. Qiang, and P. Zhu, “Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy,” *Journal of Clinical Immunology*, vol. 33, no. 1, pp. 151–161, 2013.

[8] X. Zhang, P. Wang, Y. F. Wu et al., “Allogeneic blood transfusion alleviates hip joint pain induced by ankylosing spondylitis,” *Chinese Journal of Tissue Engineering Research*, vol. 18, no. 9, pp. 1465–1470, 2014.

[9] H. Guo, M. Zheng, K. Zhang et al., “Functional defects in CD4+CD25hiFoxP3+ regulatory cells in ankylosing spondylitis,” *Scientific Reports*, vol. 6, no. 1, 2016.

[10] M. Wang, C. Liu, A. Bond et al., “Dysfunction of regulatory T cells in patients with ankylosing spondylitis is associated with a loss of Tim-3,” *International Immunopharmacology*, vol. 59, pp. 53–60, 2018.

[11] L. Limón-Camacho, M. I. Vargas-Rojas, J. Vázquez-Mellado et al., “In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis,” *The Journal of Rheumatology*, vol. 39, no. 4, pp. 830–835, 2012.

[12] M. Bonelli, J. S. Smolen, and C. Scheinecker, “Treg and lupus,” *Annals of the Rheumatic Diseases*, vol. 69, Supplement 1, pp. i65–i66, 2010.

[13] N. Arenas-Ramírez, J. Woytschak, and O. Boyman, “Interleukin-2: biology, design and application,” *Trends in Immunology*, vol. 36, no. 12, pp. 763–777, 2015.

[14] D. Cao, R. van Vollenhoven, L. Klareskog, C. Trollino, and V. Malmström, “CD25highCD4 regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease,” *Arthritis Research & Therapy*, vol. 6, no. 4, pp. R335–R346, 2004.

[15] S. Létourneau, C. Krieg, G. Pantaleo, and O. Boyman, “IL-2 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets,” *The Journal of Allergy and Clinical Immunology*, vol. 123, no. 4, pp. 758–762, 2009.

[16] S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” *Science*, vol. 299, pp. 1057–1061, 2003, J Immunol, 2017, 198(3): 981-985.

[17] J. L. Suen, H. T. Li, Y. J. Jong, B.-L. Chiang, and J.-H. Yen, “Altered homeostasis of CD4+Foxp3+ regulatory T-cell subpopulations in systemic lupus erythematosus,” *Immunology*, vol. 127, no. 2, pp. 196–205, 2009.

[18] A. H. Banham, “Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells,” *Trends in Immunology*, vol. 27, no. 12, pp. 541–544, 2006.

[19] J. Sun, D. N. Tang, T. Fu, and P. Sharma, “Identification of human regulatory T cells in the setting of T-cell activation
and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide,” Cancer Discovery, vol. 2, no. 2, pp. 122–130, 2012.

[20] Y. H. Lee, Y. Ishida, M. Rifa'i, Z. Shi, K. Isobe, and H. Suzuki, “Essential role of CD8 CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 180, no. 2, pp. 825–832, 2008.

[21] R. Han, X. Yang, M. Chen et al., “Changes and clinical significance of CD8+CD122+ T cells in the peripheral blood of patients with ankylosing spondylitis,” Clinical Rheumatology, vol. 37, no. 3, pp. 639–646, 2018.

[22] F. Ciccia, A. Accardo-Palumbo, A. Giardina et al., “Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response,” Arthritis and Rheumatism, vol. 62, no. 12, pp. 3625–3634, 2010.

[23] C. Dejaco, C. Duftner, A. Klauser, and M. Schirmer, “Altered T-cell subtypes in spondyloarthritides, rheumatoid arthritis and polymyalgia rheumatica,” Rheumatology International, vol. 30, no. 3, pp. 297–303, 2010.

[24] Y. Shan, C. Qi, J. Zhao et al., “Higher frequency of peripheral blood follicular regulatory T cells in patients with new onset ankylosing spondylitis,” Clinical and Experimental Pharmacology & Physiology, vol. 42, no. 2, pp. 154–161, 2015.

[25] D. Xu, J. Fan, Q. Chen, K. Qin, X. Li, and C. Gao, “Low dose IL-2 therapy can recovery Th17/Treg cell balance in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 76, p. 63, 2017.

[26] S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984.

[27] R. DerSimianon and R. Kacker, “Random-effects model for meta-analysis of clinical trials: an update,” Contemporary Clinical Trials, vol. 28, no. 2, pp. 105–114, 2007.

[28] S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P. Gaisford, and A. Calin, “A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index,” The Journal of Rheumatology, vol. 21, no. 12, pp. 2286–2291, 1994.

[29] F. Forger, P. M. Villiger, and M. Ostensen, “Pregnancy in patients with ankylosing spondylitis: do regulatory T cells play a role?,” Arthritis and Rheumatism, vol. 61, no. 2, pp. 279–283, 2009.

[30] M. H. Chen, W. S. Chen, H. T. Lee, C.-Y. Tsai, and C.-T. Chou, “Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis,” Clinical Rheumatology, vol. 30, no. 9, pp. 1181–1187, 2011.

[31] H. T. Liao, Y. F. Lin, C. Y. Tsai, and C.-T. Chou, “Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment,” Joint, Bone, Spine, vol. 82, no. 6, pp. 423–427, 2015.

[32] É. Toussirot, P. Saas, M. Deschamps et al., “Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity,” Arthritis Research & Therapy, vol. 11, no. 4, article R101, 2009.

[33] H. Appel, P. Wu, R. Scheer et al., “Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritides,” The Journal of Rheumatology, vol. 38, no. 11, pp. 2445–2451, 2011.

[34] Y. Gao, Y. Song, Y. X. Fan et al., “The alteration of Th7 cells and CD4+CD25+FoxP3+ regulatory T cells in patients with ankylosing spondylitis,” Chinese Journal of Microbiology and Immunology, vol. 32, no. 4, pp. 318–322, 2012.

[35] C. Wang, Q. Liao, Y. Hu, and D. Zhong, “T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis,” Experimental and Therapeutic Medicine, vol. 9, no. 1, pp. 250–256, 2015.

[36] E. T. Dunn, E. S. Taylor, S. Stebbings, M. Schultz, A. G. Butt, and R. A. Kemp, “Distinct immune signatures in the colon of Crohn’s disease and ankylosing spondylitis patients in the absence of inflammation,” Immunology and Cell Biology, vol. 94, no. 5, pp. 421–429, 2016.

[37] Z. Gula, M. Stec, M. Rutkowska-Zapala et al., “The absolute number of circulating nonclassical (CD14+CD16+) monocytes negatively correlates with DAS28 and swollen joint count in patients with peripheral spondyloarthritids,” Polish Archives of Internal Medicine, vol. 127, no. 12, pp. 846–853, 2017.

[38] M. J. Fattahi, H. Ahmadi, F. Jafarnezhad-Ansari et al., “Oral administration effects of β-D-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis,” Biomedicine & Pharmacotherapy, vol. 100, pp. 495–500, 2018.

[39] W. Ji, H. Li, F. Gao, Y. Chen, L. Zhong, and D. Wang, “Effects of tripterygium glycosides on interleukin-17 and CD4+CD25+CD127low regulatory T-cell expression in the peripheral blood of patients with ankylosing spondylitis,” Biomedical Reports, vol. 2, no. 4, pp. 517–520, 2014.

[40] Z. Duan, Y. Gui, C. Li et al., “The immune dysfunction in ankylosing spondylitis patients,” Bioscience Trends, vol. 11, no. 1, pp. 69–76, 2017.

[41] S. Dulic, Z. Vásárhelyi, A. Bajnok et al., “Analysis of the T-cell subset composition in ankylosing spondylitis patients with long-standing anti-TNF therapy,” Annals of the Rheumatic Diseases, vol. 76, p. 780, 2017.

[42] C. Lukas, R. Landewe, J. Sieper et al., “Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 18–24, 2009.

[43] D. van der Heijde, E. Lie, T. K. Kvien et al., “ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 68, no. 12, pp. 1811–1818, 2009.

[44] P. Machado, R. Landewe, E. Lie et al., “Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores,” Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 47–53, 2011.

[45] S. Sakaguchi, “Regulatory T cells: history and perspective,” Methods in Molecular Biology, vol. 707, pp. 3–17, 2011.

[46] K. Bidad, E. Salehi, A. Jamshidi et al., “Effect of all-transretinoic acid on Th17 and T regulatory cell subsets in patients with ankylosing spondylitis,” The Journal of Rheumatology, vol. 40, no. 4, pp. 476–483, 2013.

[47] S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases,” The Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995.

[48] C. Baecher-Allan, J. A. Brown, G. J. Freeman, and D. A. Hafler, “CD4+CD25high regulatory cells in human peripheral blood,”...
The Journal of Immunology, vol. 167, no. 3, pp. 1245–1253, 2001.

G. M. Han, N. J. O’Neil-Andersen, R. B. Zurier, and D. A. Lawrence, “CD4"CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis,” *Cellular Immunology*, vol. 253, no. 1-2, pp. 92–101, 2008.

C. Dejaco, C. Dufnner, and M. Schirmer, “Are regulatory T-cells linked with aging?,” *Experimental Gerontology*, vol. 41, no. 4, pp. 339–345, 2006.

L. Lu, J. Barbi, and F. Pan, “The regulation of immune tolerance by FOXP3,” *Nature Reviews Immunology*, vol. 17, no. 11, pp. 703–717, 2017.

M. Noack and P. Miossec, “Th17 and regulatory T cell balance in autoimmune and inflammatory diseases,” *Autoimmunity Reviews*, vol. 13, no. 6, pp. 668–677, 2014.

Y. Y. Wan and R. A. Flavell, “Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression,” *Nature*, vol. 445, no. 7129, pp. 766–770, 2007.

S. Nadkarni, C. Mauri, and M. R. Ehrenstein, “Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β,” *The Journal of Experimental Medicine*, vol. 204, no. 1, pp. 33–39, 2007.

M. Bonelli, A. Savitskaya, C. W. Steiner, E. Rath, J. S. Smolen, and C. Scheinecker, “Phenotypic and functional analysis of CD4"CD25 Foxp3+ T cells in patients with systemic lupus erythematosus,” *The Journal of Immunology*, vol. 182, no. 3, pp. 1689–1695, 2009.

H. X. Yang, W. Zhang, L. D. Zhao et al., “Are CD4-CD25 Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?,” *Arthritis Research & Therapy*, vol. 11, no. 5, article R153, 2009.

W. Liu, A. L. Putnam, Z. Xu-Yu et al., “CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells,” *Journal of Experimental Medicine*, vol. 203, no. 7, pp. 1701–1711, 2006.

D. J. Hartigan-O’Connor, C. Poon, E. Sinclair, and J. M. McCune, “Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells,” *Journal of Immunological Methods*, vol. 319, no. 1-2, pp. 41–52, 2007.

S. F. Ziegler, “FOXp3: of mice and men,” *Annual Review of Immunology*, vol. 24, pp. 209–226, 2006.

E. Xystrikas, A. S. Dejean, I. Bernard et al., “Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation,” *Blood*, vol. 104, no. 10, pp. 3294–3301, 2004.

G. Churlaud, F. Pitoiset, F. Jebbawi et al., “Human and mouse CD8"CD25"FOXP3" regulatory T cells at steady state and during interleukin-2 therapy,” *Frontiers in Immunology*, vol. 6, p. 171, 2015.

L. Ye, L. Zhang, J. Goodall, H. Gaston, and H. Xu, “Altered frequencies of regulatory T-cell subsets in ankylosing spondylitis and rheumatoid arthritis patients and their response to anti-TNF therapy,” *Rheumatology*, vol. 52, pp. 135–136, 2013.

M. Miyara, Y. Yoshioka, A. Kito et al., “Functional delineation and differentiation dynamics of human CD4 T cells expressing the Foxp3 transcription factor,” *Immunity*, vol. 30, no. 6, pp. 899–911, 2009.

L. S. Taams, J. Smith, M. H. Rustin, M. Salmon, L. W. Poulter, and A. N. Akbar, “Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis-prone population,” European Journal of Immunology, vol. 31, no. 4, pp. 1122–1131, 2001.

N. J. Booth, A. J. McQuaid, T. Sobande et al., “Different proliferative potential and migratory characteristics of human CD4 regulatory T cells that express either CD45RA or CD45RO,” *The Journal of Immunology*, vol. 184, no. 8, pp. 4317–4326, 2010.

V. Lazarevic, L. H. Glimcher, and G. M. Lord, “T-bet: a bridge between innate and adaptive immunity,” *Nature Reviews Immunology*, vol. 13, no. 11, pp. 777–789, 2013.

M. A. Koch, G. Tucker-Heard, N. R. Perdue, J. R. Killebrew, K. B. UrdaI, and D. J. Campbell, “The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation,” *Nature Immunology*, vol. 10, no. 6, pp. 595–602, 2009.

M. L. Sprouse, M. A. Scavuzzo, S. Blum et al., “High self-reactivity drives T-bet and potentiates Treg function in tissue-specific autoimmunity,” *JCI Insight*, vol. 3, no. 2, 2018.

Y. Chung, S. Tanaka, F. Chu et al., “Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions,” *Nature Medicine*, vol. 17, no. 8, pp. 983–988, 2011.

I. Wollenberg, A. Agua-Doce, A. Hernández et al., “Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells,” *The Journal of Immunology*, vol. 187, no. 9, pp. 4553–4560, 2011.

L. Cari, F. De Rosa, G. Nocentini, and C. Riccardi, “Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory T cells: a review of the empirical evidence and clinical applications,” *International Journal of Molecular Sciences*, vol. 20, no. 5, 2019.

N. A. Azab, I. H. Bassyouni, Y. Emad, G. A. A. El-Wabah, G. Hamdy, and M. A. Mashahit, “Human anergic/suppressive CD4+CD25+ regulatory T cells linked with aging?,” *Autoimmunity Reviews*, vol. 19, no. 4, pp. 3294–3301, 2020.

G. Hamdy, and M. A. Mashahit, “Functional delineation and differentiation dynamics of human CD4 T cells expressing the Foxp3 transcription factor,” *Immunity*, vol. 30, no. 6, pp. 899–911, 2009.
maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo,” Clinical and Developmental Immunology, vol. 2013, Article ID 238035, 12 pages, 2013.

[79] C. Lina, W. Conghua, L. Nan, and Z. Ping, "Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis," Journal of Clinical Immunology, vol. 31, no. 4, pp. 596–605, 2011.

[80] D. X. Nguyen and M. R. Ehrenstein, "Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis," The Journal of Experimental Medicine, vol. 213, no. 7, pp. 1241–1253, 2016.

[81] X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky, "Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus," The Journal of Immunology, vol. 178, no. 4, pp. 2579–2588, 2007.

[82] S. X. Zhang, X. W. Ma, Y. F. Li et al., “The proportion of regulatory T cells in patients with systemic lupus erythematosus: a meta-analysis,” Journal of Immunology Research, vol. 2018, Article ID 7103219, 11 pages, 2018.